180 Life Sciences (ATNF) has a profit margin of -18437.01%, below the Healthcare sector average of 14.34%.
Get informed when a big investor buys or sells
+ FollowAs of Mar 2026
Trailing 12 months ending Mar 2026
180 Life Sciences (ATNF) currently reports a profit margin of -18437.01% as of March 2026. That is below the Healthcare sector average of 14.34%. Use the charts on this page to explore 180 Life Sciences's profit margin history and peer comparisons.
180 Life Sciences's profit margin of -18437.01% is lower than the Healthcare sector average of 14.34%. That is roughly 128627.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' profit margin, but 180 Life Sciences's current -18437.01% should be judged against Healthcare norms (sector average: 14.34%) and against ATNF's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current profit margin of -18437.01%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 14.34%. From there, open related valuation or income-statement pages for 180 Life Sciences, and consider following ATNF for alerts when major investors trade the stock.
180 Life Sciences is classified in the Healthcare sector. On profit margin, it currently shows -18437.01% versus a sector average near 14.34%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ATNF with unrelated industries.